Axsome Therapeutics Inc

Director, Global Scientific Publications (East Coast Based Candidates Only)

United States

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, Biotechnology, Medical ResearchIndustries

Director, Global Scientific Publications

Employment Type: Full time

Company Information

PTC Therapeutics is a global commercial biopharmaceutical company. For over 25 years, our team has been deeply committed to a unified purpose: Extending life’s moments for children and adults living with a rare disease.

At PTC, we cultivate an inclusive culture where everyone feels valued, respected, and empowered. We welcome candidates from all backgrounds to join our team, fostering a strong sense of belonging.

Visit our website to learn more about our company and culture: www.ptcbio.com

Position Overview

The Director, Global Scientific Publications is responsible for the management and delivery of scientific publications in alignment with brand/therapeutic area publication plans. This includes, but may not be limited to, working with internal stakeholders, vendors, and healthcare professionals to review and provide scientific consultation regarding publication-related material across all therapeutic areas. The incumbent may also develop scientific content for publications supporting the objectives of the Global Medical Affairs function.

The Director, Global Scientific Publications enhances the effectiveness of our external relationships and collaborations by managing and optimizing the publication team’s collaborations with authors, vendors, and internal stakeholders to ensure the highest quality and accuracy of our communication materials and related publication activities. The Director manages direct report(s).

The incumbent works cross-functionally with internal departments and external resources on scientific publication-related issues. The Director, Global Scientific Publications ensures adherence to relevant regulatory requirements, company Standard Operating Procedures (SOPs), and industry standards as appropriate.

Responsibilities

  • Works closely with internal and external stakeholders in a matrix environment to develop and deliver scientific publications and related communications across all commercialized and emerging product and therapeutic areas as needed. This includes collaboration with the Medical Affairs lead of the relevant therapeutic areas (the owners of the scientific publication plans) as well as Global Project Leaders.
  • When necessary, acts as liaison representing the Global Scientific Publications function at intra- and interdepartmental meetings, participating in decisions that impact the overall medical/scientific support of products within the therapeutic and asset teams.
  • Strategizes and collaborates with key internal and external stakeholders to identify target publication opportunities.
  • Coordinates timely and on-budget completion of publication activities with external and internal medical writers, publishing agencies, and other vendors as appropriate.
  • Monitors the publication requirements of and deadlines for key international/national congresses and journals.
  • Defines the operational milestones of the publication plans across all therapeutic areas.
  • Coordinates the review of scientific proposals and publications by the PTC Publication Steering and Review Committee members as well as PTC senior management in accordance with internal and industry-wide standard operating procedures and guidelines.
  • Coordinates local abstracts and scientific publications in collaboration with local PTC affiliates and Medical Affairs colleagues.
  • Submits abstracts, posters, and clinical papers according to publication plan(s) and tracks the progress.
  • Documents all relevant communication, reviews, and approvals according to good publication practice through PubSTRAT.
  • Attends scientific congresses if needed and collaborates with authors and internal colleagues on the presentation of abstracts, posters, and clinical papers.
  • Applies scientific and business acumen relevant to therapeutic areas, products, emerging therapies, and competitive intelligence to the objectives of scientific publication plan(s). This involves interpreting medical literature to assist in the production of ...

Requirements

  • (Information not provided in the original text)

Application Instructions

  • (Information not provided in the original text)

Skills

Scientific Publications
Scientific Content Development
Publication Management
Stakeholder Collaboration
Regulatory Compliance
Medical Affairs
Vendor Management
Cross-functional Communication

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.
Potential delays in AXS-07 launch amid growing market anticipation.
Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.
AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI